Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 07:30 ET | Source: Kamari Pharma

Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the International Pachyonychia Congenita Consortium Symposium

Preclinical results presented demonstrate KM-023 is a highly effective and selective oral TRPV3 inhibitor KM-023 normalized cells proliferation and differentiation in 3D pachyonychia congenita skin...
May 17, 2024 14:30 ET | Source: Kamari Pharma

Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita In vitro and in vivo...
April 30, 2024 09:00 ET | Source: Kamari Pharma

Kamari Pharma Appoints Dr. John Doux to its Board of Directors

NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
April 16, 2024 16:05 ET | Source: Kamari Pharma

Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology

Late breaking poster presentation includes Phase 1b clinical trial results demonstrating the safety and preliminary efficacy of KM-001, a topical TRPV3 inhibitor, for the treatment of palmoplantar...